438 related articles for article (PubMed ID: 31285776)
1. Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer.
Zhao Z; Li Y; Shukla R; Liu H; Jain A; Barve A; Cheng K
Theranostics; 2019; 9(15):4508-4524. PubMed ID: 31285776
[TBL] [Abstract][Full Text] [Related]
2.
Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
[TBL] [Abstract][Full Text] [Related]
3. Co-delivery of EGFR and BRD4 siRNA by cell-penetrating peptides-modified redox-responsive complex in triple negative breast cancer cells.
Zhang C; Yuan W; Wu Y; Wan X; Gong Y
Life Sci; 2021 Feb; 266():118886. PubMed ID: 33310044
[TBL] [Abstract][Full Text] [Related]
4. Low-weight polyethylenimine cross-linked 2-hydroxypopyl-β-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA.
Li JM; Wang YY; Zhang W; Su H; Ji LN; Mao ZW
Int J Nanomedicine; 2013; 8():2101-17. PubMed ID: 23766646
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer.
Zhao Z; Li Y; Liu H; Jain A; Patel PV; Cheng K
Sci Adv; 2020 Jul; 6(29):eabb0616. PubMed ID: 32832636
[No Abstract] [Full Text] [Related]
6. Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate.
Park K; Lee MY; Kim KS; Hahn SK
Biomaterials; 2010 Jul; 31(19):5258-65. PubMed ID: 20378167
[TBL] [Abstract][Full Text] [Related]
7. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.
Lu ZX; Liu LT; Qi XR
Int J Nanomedicine; 2011; 6():1661-73. PubMed ID: 21904456
[TBL] [Abstract][Full Text] [Related]
8. Nanosized functional miRNA liposomes and application in the treatment of TNBC by silencing Slug gene.
Yan Y; Li XQ; Duan JL; Bao CJ; Cui YN; Su ZB; Xu JR; Luo Q; Chen M; Xie Y; Lu WL
Int J Nanomedicine; 2019; 14():3645-3667. PubMed ID: 31190817
[No Abstract] [Full Text] [Related]
9. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer cell-specific VEGF siRNA delivery system using cell targeting peptide conjugated polyplexes.
Kim SH; Lee SH; Tian H; Chen X; Park TG
J Drug Target; 2009 May; 17(4):311-7. PubMed ID: 19242850
[TBL] [Abstract][Full Text] [Related]
11. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer.
Kim SH; Jeong JH; Lee SH; Kim SW; Park TG
J Control Release; 2008 Jul; 129(2):107-16. PubMed ID: 18486981
[TBL] [Abstract][Full Text] [Related]
12. A single-monomer derived linear-like PEI-co-PEG for siRNA delivery and silencing.
Tsai LR; Chen MH; Chien CT; Chen MK; Lin FS; Lin KM; Hwu YK; Yang CS; Lin SY
Biomaterials; 2011 May; 32(14):3647-53. PubMed ID: 21324524
[TBL] [Abstract][Full Text] [Related]
13. Cell-Penetrating Peptide-Modified Graphene Oxide Nanoparticles Loaded with Rictor siRNA for the Treatment of Triple-Negative Breast Cancer.
Yang YY; Zhang W; Liu H; Jiang JJ; Wang WJ; Jia ZY
Drug Des Devel Ther; 2021; 15():4961-4972. PubMed ID: 34916779
[TBL] [Abstract][Full Text] [Related]
14. A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes.
Werth S; Urban-Klein B; Dai L; Höbel S; Grzelinski M; Bakowsky U; Czubayko F; Aigner A
J Control Release; 2006 May; 112(2):257-70. PubMed ID: 16574264
[TBL] [Abstract][Full Text] [Related]
15. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
[TBL] [Abstract][Full Text] [Related]
17. Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles.
Liu Y; Zhu YH; Mao CQ; Dou S; Shen S; Tan ZB; Wang J
J Control Release; 2014 Oct; 192():114-21. PubMed ID: 25016158
[TBL] [Abstract][Full Text] [Related]
18. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
19. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy.
Kim SH; Jeong JH; Lee SH; Kim SW; Park TG
J Control Release; 2006 Nov; 116(2):123-9. PubMed ID: 16831481
[TBL] [Abstract][Full Text] [Related]
20. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
